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E-mail address: takeutit@kochi-u.ac.jp (T. TakeuchHere, we report that the transcriptional regulator Zeb1 repressed the transcription of T-cadherin, to
increase the invasive activity of gallbladder cancer cells. Zeb1 physically bound to the promoter of
T-cadherin, repressed promoter activity in E-box-like sequence-dependent fashion, and suppressed
T-cadherin expression. In gallbladder cancer tissues, Zeb1 was expressed at the cancer invasion
front, whereas T-cadherin was exclusively expressed in non-invasive foci. Collagen gel invasion
assay showed that T-cadherin was a negative regulator for gallbladder cancer invasion. These ﬁnd-
ings suggest that Zeb1 represses T-cadherin expression and thus increases the invasive activity of
gallbladder cancer.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gallbladder cancer is an aggressive tumor with strong invasive
activity into adjacent organs. It is well established that depth of
cancer invasion is strongly correlated with prognosis in patients
with gallbladder cancer [1]. Unfortunately, it is often difﬁcult to
cure advanced invasive gallbladder cancer with conventional
treatment.
Genotoxic stress is, in association with long-term inﬂammation,
important in the tumorigenesis of gallbladder cancer [2,3]. Studies
focused on molecular mechanisms of tumorigenesis have revealed
mutations of p53 [4–6], activating mutations of the KRAS proto-
oncogene [7], and loss of cell-cycle regulation by CDK-INK4A [8]
in gallbladder cancer. However, the molecular mechanisms in-
volved in gallbladder cancer invasion remain unclear.
Recent studies have highlighted epithelial-mesenchymal transi-
tion (EMT) as a crucial process in cancer invasion and metastasis
[9,10]. Cancer cells acquire ﬁbroblast-like properties by EMT as
well as increased motility. In the process of EMT, transcription fac-
tors such as Snails, bHLH, and Zebs repress the expression of
various epithelial cell-related genes including E-cadherin while
up-regulating the expression of mesenchymal cell-related genes
[11,12].chemical Societies. Published by E
i).T-cadherin (also referred to as CDH13 or H-cadherin) is a glyco-
syl phosphatidyl inositol (GPI)-linked surface membrane protein
[13], and is expressed in various epithelial cells [14,15]. T-cadherin
lacks a cytoplasmic domain, which is required for the homophilic
binding activity of classical cadherins [16]. Moreover, a tryptophan
conserved in all other cadherins and which plays a crucial role in
adhesive function is replaced by an isoleucine in T-cadherin. Given
these unique molecular structural features, and its localization on
the lipid raft, which partitions various signaling molecules, T-
cadherin is thought to play roles in signal transduction apart from
cell-cell adhesion [17–20]. Consistent with this, NMR analysis very
recently demonstrated that T-cadherin exhibits little structural
evidence of homophilic adhesive activity [21].
Interestingly, many epigenetic studies focused on analysis of
promoter methylation have suggested that T-cadherin acts as a tu-
mor suppressor factor in various malignant tumors including those
of breast, lung, colon, and skin [14,22–25]. We have examined the
pathobiological properties of T-cadherin in various cancers, and
noted the presence of a typical E-box-like (also designated as E2-
box) element, 50-CACCTG-30 [26], to which Zeb1 could bind, in
the promoter region of T-cadherin [24,27].
Here, we report that Zeb1 repressed the transcription of T-
cadherin and down-regulation of T-cadherin increased cancer
invasion activity in gallbladder cancer cell. We think that Zeb1-
mediated repression of T-cadherin may be involved in gallbladder
cancer invasion. Since restoration of T-cadherin in culturedlsevier B.V. All rights reserved.
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ity, T-cadherin could be a possible target for corrective gene
therapy.
2. Materials and methods
2.1. Antibodies
A rabbit polyclonal antibody to human Zeb1 was prepared in
our laboratory using the methods of Darling et al. with modiﬁca-
tions [28,29]. Brieﬂy, PCR product encoding a part of human Zeb1
(amino acids 559–663) was subcloned into the PET16b vector
(Novagen Inc., Madison, WI) and conﬁrmed by sequence analysis.
Recombinant histidine-tagged protein was obtained using trans-
formed BL21 (DE3) pLyS cells by isopropyl-1-thio-beta-D-galacto-
pyranoside induction, subsequently puriﬁed with a Ni-NTA Spin
kit (Qiagen, Valencia, CA), and used for immunization of rabbits.
Recombinant GST-fused Zeb1 (amino acids 559–663) protein was
also obtained using the pGEX-5X-1 vector (Amersham Pharmacia
Biotech, Piscataway, NJ) and used for afﬁnity-column preparation.
The speciﬁcity of afﬁnity-puriﬁed antibody was conﬁrmed byWes-
tern-immunoblotting and immunohistochemical staining using
well characterized Zeb-1-expressing uterine carcinosarcoma tissue
(Supplementary Fig. S1). Details of the procedures used to prepare
afﬁnity-puriﬁed rabbit speciﬁc antibody to human T-cadherin have
been described previously [14,17,25]. Antibodies to MHC class I
and vimentin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Monoclonal mouse immunoglobulin antibodies
to N-cadherin were purchased from Zymed Laboratories Inc. (San
Francisco, CA) and E-cadherin from Takara Bio Inc. (Shiga, Japan).
Normal control immunoglobulin was prepared in our laboratory.
2.2. Chromatin immunoprecipitation (ChIP) analysis
Zeb1-expressing but T-cadherin-negative NOZ cells were cross-
linked with 1% formaldehyde for 10 min. Cells were suspended in
0.2 ml of SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH
8.0) for 10 min. Genomic DNA was fragmented to lengths of 200–
1000 bp by sonication and diluted 10-fold with ChIP dilution buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris–HCl,
pH 8.1, 167 mM NaCl). One-tenth of the sample was set aside as
an input control, and the remainder was pre-cleared with salmon
sperm DNA protein A-Sepharose beads for 30 min with agitation
and subsequently incubated with rabbit polyclonal anti-Zeb1 anti-
body or normal anti-rabbit IgG as a negative control overnight at
4 C. Immune complexes were pulled down with salmon sperm
DNA protein A-Sepharose beads, eluted with elution buffer (1%
SDS, 0.1 M NaHCO3), and incubated with 5 M NaCl for 4 h at
65 C to reverse cross-linking. The elutes were treated with pro-
teinase K, and released DNA was puriﬁed and ampliﬁed by PCR
with primers speciﬁc for the T-cadherin promoter (sense, 50-TAC
TGC TGT TCT GAG TAC CTG-30/62220–62200; antisense, 50-GTG
GCC CAA GTC ATG ATG GTG-30/61955–61975 of Homo sapiens
chromosome 16 clone RP11-2L4).
2.3. Electrophoretic mobility shift assay (EMSA)
The entire coding region of human Zeb1 cDNAwas generated by
RT-PCR with SpeedStar polymerase (Takara) with the sense primer
50-GCCATGGCGGATGGCCCCAGGTGTAAG-30 and anti-sense primer
50-TTAGGCTTCATTTGTCTTTTCTTCAGAC-30, subsequently ligated
into pTarget-T expression vector (Promega, Madison, WI), and
conﬁrmed by sequencing. Transfection into Cos7 cells was carried
out as described previously [28]. Nuclear lysates were prepared
from Cos7 cells, which were transfected with Zeb1-containing
pTarget-T.EMSA was performed using the digoxigenin Gel Shift kit accord-
ing to the manufacture’s protocol (Roche Applied Science, Mann-
heim, Germany). Brieﬂy, a double-strand probe (683 to 602)
containing the wild E2-box 50-CACCTG-30, or replaced by 50-
AAATTT-30 sequences, were end-labeled with digoxigenin-11-
ddUTP. Labeled probes were added to nuclear extract, and the
binding reaction was allowed to proceed for 15 min at room tem-
perature. Unlabeled competitor at 50-fold molar excess, or anti-
bodies, anti-Zeb1 or control antibody were added to the binding
reactions 5 min before the labeled probe and allowed to incubate
at room temperature.
The samples were resolved through a non-denaturing 8% acryl-
amide gel for separating complexes, subsequently transferred to a
nylon membrane using electroblotter, and further handled for
immunochemical detection as outlined by the manufacturer.2.4. Repression of T-cadherin promoter activity by Zeb1
The procedure used for evaluation of promoter activity using
the GreatEscApeTMSEAP system (Takara) was described in detail
previously [28]. The T-cadherin promoter sequence from 1 to
682 was cloned into pSEAP2-Basic plasmid (Takara) between
BamH1 and EcoR1 restriction sites, and subsequently conﬁrmed
by sequencing. Wild-type and E2-box-mutated promoters were
generated by PCR with different 50 primers and a ﬁxed 30 primer,
using human genomic DNA as template. The sequence of the single
reverse primer was 50-GGA ATT CAT TTT GTC CGA CTA GAA GCG-30
(1 to 18), while the forward primers were 50-AGG ATC CAG ACT
CTC ACC TGA GCA GTT-30 (663 to 682; E2-box underlined) and
50-AGG ATC CAG ACT CTA AAT TTA GCA GTT-30 (E2-box sequence
replaced by underlined sequence) for wild-type and E2-box-
mutated sequences, respectively.
Wild-type, E2-box-mutated T-cadherin promoter-containing
pSEAP2-Basic vectors, or empty vector, and Zeb1-containing pTar-
get-T vectors were co-transfected into Cos7 cells using DEAE-Dex-
tran. Promoter activity was measured using a GreatEscApeTMSEAP
chemiluminescent detection kit (Takara). Reporter assays was also
performed in the cultured gallbladder cancer cell, OCUG-1, and
stably Zeb1 overexpressing OCUG-1 cell, which was described be-
low. In these assays, wild-type, E2-box-mutated T-cadherin pro-
moter-containing pSEAP2-Basic vectors, or empty vector, was
transfected.
2.5. Western-immunoblotting
Western-immunoblotting was carried out according to the
modiﬁed method of Towbin et al. [30], as previously reported
[14]. Brieﬂy, equal amounts of proteins were electrophoresed in
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE) gels and electroblotted to polyvinylidine diﬂuoride
membrane (Millipore, Bedford, MA). After blocking with bovine
serum albumin, membranes were incubated with antibodies.
2.6. Cell culture
NOZ [31,32] and OCUG-1 [32] gallbladder cancer cells were ob-
tained from the Japan Health Science Research Resources Bank
(Osaka, Japan). Both NOZ cell and OCUG-1 cells are derived from
the malignant peritoneal effusion of patient with gallbladder ade-
nocarcinoma. NOZ cell line composed of spindle and round shaped
cells, while OCUG-1 cells proliferated in a monolayer sheet.
Cells were cultured in Dulbecco’s modiﬁed Eagle’s medium (D-
MEM) (Gibco Life Technologies, NY) containing 10% heat-inacti-
vated fetal bovine serum (FBS) and 50 lg/ml gentamycin (Gibco
RL-Life Technologies, Grand Island, NY).
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Archival pathological tissue specimens were obtained from 30
patients with invasive gallbladder cancer. The 30 gallbladder carci-
nomas (age 54–76 years; average age 64.6 years; 24 women and 6
men) comprised advanced cases (pT2 10, pT3 12, pT4 8). Of these,
eight cases (26.7%) were classiﬁed as well-differentiated, 18 cases
(60%) as moderately differentiated, and four cases (13.3%) as poorly
differentiated adenocarcinomas. TNM staging according to the
staging system of the American Joint Committee on Cancer (AJCC)
was used [33]. All specimens were surgically obtained, ﬁxed in 10%
buffered formalin, and parafﬁn-embedded. The procedures used
for immunohistochemical staining were previously described in
detail [14]. In several experiments, antibodies were preadsorbed
with antigens to verify speciﬁcity.
2.8. siRNA mediated RNA interference
Using the methods of Philippova et al. [34], we employed the
siRNA duplexes 50-GGACCAGUCAAUUCUAAAC-30 for T-cadherin
gene silencing. For ZEB1 gene silencing, we examined thee siRNA
duplexes (Sigma Genosys siRNA Service, St. Louis, MO) and
employed 50-CCCAUUACAGGCAACCAGUTT-30 (Supplementary Fig.
S2). We also used GFP siRNA duplex, with a target sequence 50-
CGGCAAGCUGACCCUGAAGUUCAU-30, as a non-silencing control.
siRNA was transfected into gallbladder cancer cells using Oligofec-
tamine following the manufacturer’s instructions (Invitrogen Life
Sciences, Carlsbad, CA).
2.9. Tetracycline-induced T-cadherin expression system
The human T-cadherin cDNA sequence was subcloned into
pcDNA4/TO/myc-HisA vector (Invitrogen). The resulting vector,
designated pcDNA4/TO/T-cad, allowed T-cadherin expression un-
der the control of a tetracycline operator 2 sequence-containing
cytomegalovirus promoter. The NOZ cell line was ﬁrst stably trans-
fected with the pcDNA6/TR vector (Invitrogen), containing se-
quences encoding the tetracycline repressor protein, using
DOTAP transfection reagents (Boehringer Mannheim GmbH,
Mannheim, Germany). The bulk population was subsequently
transfected with pcDNA4/TO/T-cad plasmid and selected with Zeo-
cin and Blasticidin (Invitrogen). Finally, we established three inde-
pendent clones which expressed T-cadherin in the presence of
1 lg/ml tetracycline (Supplementary Fig. S3).
2.10. Reverse-transcriptase polymerase chain reaction (RT-PCR) and
quantitative real-time PCR (TaqMan technology)
RT-PCR was performed as previously described [17]. Brieﬂy, to-
tal cellular RNA was prepared from cell lysates using RNA-zol B
(Biotex Laboratory, Houston, TX). cDNA synthesis from total RNA
and subsequent PCR were performed using an RNA LA (long and
accurate) PCR kit (Takara). The procedure was performed according
to the manufacturer’s protocol. The primer sets used in this study
were sense 50-GCCACGATCATGATCGATGAC-30 and antisense 50-
GTCTTCATTTTCCACTTTGA-30 for T-cadherin, sense 5-TTCAGCAT-
CACCAGGCAGTC-3 and antisense 5-GAGTGGAGGAGGCTGAGTAG-
3 for Zeb1, and sense 50-TCCACCACCCTGTTGCTGTA-30 and
antisense 50-ACCACAGTCCATGCCATCAC-30 for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The PCR-ampliﬁed products
were electrophoretically separated on a 2% agarose gel.
Real-time PCR was also carried out according to the manufac-
turer’s protocols (Prism 7000, Applied Biosystems (ABI), Foster
City, CA). The primer/probes Hs 00169908-ml (T-cadherin) and
Hs 99999905-ml (GAPDH) were purchased from ABI. Levels of
expression of T-cadherin were calculated using the comparativecycle time (Ct) value, which was normalized to GAPDH PCR Ct value
by subtracting the GAPDH Ct value from the target PCR Ct value to
obtain DCt. From DCt, the relative level of mRNA expression to that
of GAPDH for T-cadherin was calculated using the following equa-
tion: relative mRNA expression = 2(Ct targetCt GAPDH). Real-time PCR
was performed in triplicate.
2.11. Cell proliferation and collagen gel invasion assay
Cell proliferation was evaluated by measurement of live cells as
previously described [14]. Brieﬂy, 1  103 siRNA-treated OCUG-1
cells were cultured on standard 35 mm tissue culture dishes (BD
Falcon, San Jose, CA) in triplicate. After 24 and 48 h, live cells were
counted.
Collagen gel invasion assay was carried out using collagen solu-
tion (type I-A) (Nitta Gelatin, Osaka, Japan). Brieﬂy, 100 ll of colla-
gen gel was set within a 6.5 mm diameter, 8 lm pore ﬁlter
transwell (Corning Costar, Corning, NY). Then 2  104 cells were
plated in 100 ll serum-free DMEM, and 1 ml of DMEM supple-
mented with 10% FCS and recombinant hepatocyte growth factor
(ﬁnal concentration 20 lg/ml) was applied underneath the ﬁlter.
For tetracycline-induced T-cadherin expression in NOZ cells,
1 lg/ml tetracycline was added to the culture system.
Cells were then allowed to invade out of collagen I matrix across
the membrane for 24 and/or 48 h. Non-invasive cells were then re-
moved from the top compartment of the transwell with a cotton
swab and the invasive cells present on the underside of the mem-
brane were ﬁxed and stained with hematoxylin. The number of
invasive cells was counted per ﬁeld (40 microscope objective)
from a random ﬁeld of each membrane.
These assays were performed in triplicate and repeated at least
twice.
2.12. Statistical analysis
Statistical analysis was performed by Student’s t-test for
unpaired observation. Findings of P < 0.01 were considered
signiﬁcant.3. Results
3.1. Zeb1 bound and repressed the activity of T-cadherin promoter
We noted that a typical E-box-like sequence (also reported as
E2-box motif), 50-CACCTG-30, is present in the previously identiﬁed
T-cadherin promoter. RT-PCR analysis demonstrated that NOZ cells
expressed Zeb1, but non-detectable levels of T-cadherin. In con-
trast, OCUG-1 cells expressed T-cadherin but not Zeb1 (Fig. 1A).
Using NOZ cells, we performed ChIP assay to determine
whether the T-cadherin promoter is a direct target of Zeb1. As
demonstrated in Fig. 1B, we found a T-cadherin-speciﬁc PCR band
on immunoprecipitation with anti-Zeb1 antibody in NOZ gallblad-
der cancer cells. No detectable PCR products were found with con-
trol rabbit IgG. The EMSA also indicated that Zeb1 bound to the
wild-type T-cadherin promoter containing 50-CACCTG-30 sequence,
but not that with mutated 50-AAATTT-30 sequence (Fig. 1C). These
ﬁndings suggested that endogenously expressed Zeb1 bound to T-
cadherin promoter in the NOZ gallbladder cancer cell.
Because Zeb1 acts not only as a repressor but also as an activa-
tor for several genes [35], we next examined whether Zeb1 re-
pressed T-cadherin promoter activity. Exogenously expressed
Zeb1 decreased wild-type (50-CACCTG-30) but not mutated E2-
box-type (50-AAATTT-30) T-cadherin promoter activity in Cos7
(Fig. 1D). Notably, exogenous Zeb1 expression reduced T-cadherin
mRNA in OCUG-1 cell (Fig. 1E). Moreover, exogenously expressed
Fig. 1. Zeb1 directly associated with T-cadherin promoter and repressed its activity in E2-box element-dependent fashion. (A) RT-PCR demonstrated that OCUG-1 gallbladder
cancer cells expressed T-cadherin mRNA but non-detectable levels of Zeb1 mRNA, while NOZ gallbladder cancer cells expressed Zeb1 mRNA but non-detectable levels of T-
cadherin mRNA. (B) A chromatin immunoprecipitation experiment demonstrated that endogenous Zeb1 bound to the promoter region of T-cadherin. (C) Electrophoretic
mobility shift assay (EMSA). Nuclear extracts were incubated with digoxigenin-11-ddUTP–labeled probe (683 to 602), which had the wild-type E2-box 50-CACCTG-30 (Wt),
or mutated 50-AAATTT-30 sequence (Mut), and were resolved by gel electrophoresis. Unlabeled competitor at 50-fold molar excess (Cold competitor), anti-Zeb1, or control
antibody, was added to the binding reactions 5 min before the labeled probe and allowed to incubate at room temperature. The anti-Zeb1 antibody used in the present study
disrupted Zeb1 binding to the probe. Asterisk () indicates the retarded DNA–protein complex. (D) Zeb1 repressed the activity of T-cadherin promoter in E2-box element- and
dose-dependent fashion in Cos7 cells. A 5 lg portion of wild-type or E2-box-mutated T-cadherin promoter vector was co-transfected with Zeb1-expression vector (0, 0.5, or
5 lg). Signiﬁcant, dose-dependent repression of wild-type T-cadherin promoter by Zeb1 was observed. Note that E2-box-mutated promoter activity was not affected by Zeb1.
Promoter activity was measured using a GreatEscApeTM SEAP ﬂuorescence detection kit (BD Biosciences Clontech) in supernatant of cell cultures in triplicate. Percent ratio of
activity with 5 lg-wild-type T-cadherin promoter transfectant, substituted by the activity of control non-transfected Cos7 cells, was assigned a value of 100 (%). Values are
means ± S.D. (n = 3). (E) Exogenous Zeb1 expression reduced T-cadherin mRNA level in OCUG-1 cells. Independent Zeb1-expressing OCUG-1 cells clones were obtained by
transfection with pTarget-T expression vector containing Zeb1 cDNA after G418 selection. All three independent Zeb1-expressing OCUG-1 cells expressed little T-cadherin
mRNA (lanes 2, 3, and 4). An OCUG-1 cell clone, which was transfected with empty vector, expressed T-cadherin, but not Zeb1, as found in the original cells (lane 1). (F)
Promoter assay using intact OCUG-1 (indicated as wildOCUG) and Zeb1-expressing OCUG-1 (Zeb1-OCUG). The activity of T-cadherin promoter with wild-type E2-box
element was signiﬁcantly inhibited in Zeb1-expressing OCUG cells. Representative results obtained using a transfectant clone are shown. Similar results were obtained using
other transfectants.
Fig. 2. siRNA silencing of T-cadherin increased gallbladder cancer cell invasion
without affecting cell growth. T-cadherin was signiﬁcantly down-regulated with
use of speciﬁc siRNA for T-cadherin but not control siRNA (indicated by MOCK) in
OCUG-1 cells (A: Western-immunoblotting, B: real-time PCR, P < 0.01). There was
no signiﬁcant difference in growth between T-cadherin-speciﬁc siRNA-treated and
control OCUG-1 cells (C). In contrast, T-cadherin-negative OCUG-1 cells exhibited
much weaker invasive activity than control cells (D, P < 0.01). Bars represent
standard errors of the mean.
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tated E2-box-type (50-AAATTT-30) T-cadherin promoter activity in
OCUG-1 (Fig. 1F).
These ﬁndings indicate that Zeb1 repressed T-cadherin pro-
moter activity through the E2-box sequence.
3.2. T-cadherin is a negative regulator of gallbladder cancer invasion
Zeb1-mediated repression of various genes has been found to
induce EMT in cancer cells. We therefore next examined whether
down-regulation of T-cadherin altered the malignant phenotype
of gallbladder cancer. We treated T-cadherin-expressing OCUG-1
cells with T-cadherin-speciﬁc and control siRNA. Signiﬁcant silenc-
ing of T-cadherin expression was observed in OCUG-1 cells with
use of T-cadherin-speciﬁc siRNA but not control siRNA (represen-
tative ﬁndings shown in Fig. 2A and B). Interestingly, siRNA-silenc-
ing of T-cadherin increased collagen-gel invasive activity of OCUG-
1 cells without altering cell growth (Fig. 2C and D).
3.3. Effects of Zeb1and T-cadherin on cell phenotype and invasion
activity of cultured gallbladder cancer cells
We subsequently examined whether exogenous T-cadherin
expression or silencing of Zeb1 expression altered the phenotype
and invasive activity of NOZ cells. We generated a tetracycline-in-
duced T-cadherin expression system using T-cadherin-negative
NOZ cells. We established three independent clones (#2, #5, and
#6), in which T-cadherin expression was regulated by tetracycline.
In these clones, T-cadherin transcript was induced after 24 h by the
addition of 1 lg/ml tetracycline (Supplementary Fig. S2). Silencing
of Zeb1 expression was also performed in NOZ cells with use of
Zeb1-speciﬁc siRNA but not control siRNA (Supplementary Fig. S3).
We found epithelial cell-like cell clusters in the case of both T-
cadherin-expressing and Zeb1-silencing NOZ cells, whereas intact
NOZ cells exhibited mesenchymal cell feature (Fig. 3A). Notably,silencing of Zeb1 increased E-cadherin and T-cadherin expression
in NOZ cells (Fig. 3B). In contrast, silencing of Zeb1 decreased N-
cadherin expression. Both T-cadherin expression and Zeb1 silenc-
ing signiﬁcantly reduced collagen gel invasive activity of NOZ cells
(Fig. 3C).
Fig. 3. Zeb1 and T-cadherin modulated morphological phenotype and invasive
activity of NOZ gallbladder cancer cells. (A) Intact NOZ cells exhibited lymphoid and
spindle ﬁbroblast-like morphology, a feature of mesenchymal phenotype. Mono-
layer clusters with epithelial cell morphology were observed in the case of T-
cadherin-expressing and Zeb1-silencing NOZ cells. Cells were with Giemsa-stained
(original magniﬁcation, 50). (B) Western-immunoblotting. Modulation of E-
cadherin and N-cadherin expression was found in Zeb1-silencing NOZ cells, but
not in T-cadherin-expressing NOZ cells. (C) Representative result of collagen gel
invasion assay at Day1. Enforced T-cadherin expression and silencing of Zeb1
resulted in signiﬁcant down-regulation of invasive activity of NOZ cells (P < 0.01).
Values are means ± S.D. (n = 3). Fig. 4. Zeb1 and T-cadherin modulated morphological phenotype and invasive
activity of OCUG-1 gallbladder cancer cells. (A) Intact OCUG-1 cells exhibited
monolayer clusters with epithelial cell features. Notably, many ﬁbroblastic spindle
cells were observed in the case of Zeb1-expressing and T-cadherin-silencing OCUG-
1 cells. Cells were with Giemsa-stained (original magniﬁcation, 50). (B) Western-
immunoblotting. Modulation of E-cadherin, N-cadherin, and vimentin expression
was found in Zeb1-expressing and T-cadherin-silencing OCUG-1 cells. (C) Repre-
sentative result of collagen gel invasion assay at Day1. Exogenous Zeb1 expression
and down-regulation of T-cadherin expression signiﬁcantly increased the invasive
activity of OCUG-1 cells (P < 0.01). Values are means ± S.D. (n = 3).
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the phenotype and invasive activity of OCUG-1 cells as observed
for T-cadherin-silencing OCUG cells. As demonstrated in Fig. 4A,
wild-type OCUG-1 displayed the epithelial phenotype; however,
a clear morphological change, involving a spindle mesenchymal
cell phenotype, was induced by enforced Zeb1 expression and
silencing of T-cadherin expression. Down-regulation of E-cadherin,
in contrast to up-regulation of N-cadherin and vimentin, was dem-
onstrated in Zeb1-expressing OCUG-1 cells (Fig. 4B). Zeb1 expres-
sion signiﬁcantly increased collagen-gel invasive activity of OCUG-
1 cells (Fig. 4C). Notably, the invasive activity of Zeb1 expressing
OCUG-1 cells was much high than that of T-cadherin-negative
OCUG-1 cells.
These ﬁndings, together with the result of the promoter assay,
suggest that Zeb1-mediated silencing of T-cadherin facilitates the
invasion of gallbladder cancer cells in vitro. Notably, neither en-
forced T-cadherin expression in NOZ cells nor down-regulation of
T-cadherin in OCUG-1 cells affected the E-cadherin or N-cadherin
expression (Figs. 3B and 4B). Zeb1-mediated down-regulation of
T-cadherin might independently contribute to gallbladder cancer
invasion apart from the E-cadherin system.
3.4. Zeb1 and T-cadherin expression on gallbladder cancer cells
It is important to know the Zeb1 and T-cadherin expression in
gallbladder cancer tissues. We could ﬁnd no previous report that
immunohistochemically examined T-cadherin and/or Zeb1 expres-
sion in gallbladder cancer tissue specimens. Therefore, immuno-
histochemical staining was carried out using archival
pathological gallbladder cancer specimens.
Representative results are demonstrated in Fig. 5. With use of
anti-Zeb1 antibody, immunoreactivity was found in 23 of 30 inva-
sive gallbladder cancer tissue specimens, almost exclusively at
sites of cancer invasion. Notably, Zeb1 was little expressed in
non-cancerous epithelium.By contrast, T-cadherin expression was found in 13 of 30 gall-
bladder cancer tissues at non-invasive foci. Preadsorption of
antibodies with immunized antigen completely eliminated immu-
noreactivity, verifying antibody speciﬁcity. No staining was
observed in tissues examined with control antibody.
These ﬁndings indicated that Zeb1 was overexpressed at sites of
cancer invasion, where T-cadherin was not expressed.
4. Discussion
Loss of T-cadherin expression has been reported in many malig-
nant tumors [14,22–25,36–38]. Although many studies, including
our own, have demonstrated hypermethylation of T-cadherin pro-
moter in various cancers, they did not demonstrate that aberrant
methylation of the promoter region was solely responsible for
silencing of T-cadherin.
Takahashi et al., using genomic DNA from whole frozen tissues,
reported that aberrant methylation of the T-cadherin promoter
was found in 44% of gallbladder cancer specimens, most of which
were in invasive stage (45 of 50 cases) [39]. However, in the pres-
ent study, we found no signiﬁcant T-cadherin expression in inva-
sive foci of 30 gallbladder cancer specimens. It is thus likely that
molecular mechanisms other than aberrant methylation partici-
pate in T-cadherin silencing.
The T-cadherin promoter segment, which spans 1 to 682,
contains a typical canonical E2-box, 50-CACCTG-30, for binding of
Zeb1. It is known that Zeb1 represses transcription through bind-
Fig. 5. Representative immunohistochemical staining of gallbladder cancer tissues.
Zeb1 immunoreactivity was observed in invasive foci (A) but not in non-invasive
foci (C) of gallbladder cancer. In contrast, T-cadherin expression was found in non-
invasive foci (D) but not invasive foci in gallbladder cancer tissue specimens.
Contrasting staining with anti-T-cadherin antibodies at non-invasive cancer
(arrow) and anti-Zeb1 at invasive cancer (arrow head) in the same tissue specimens
were shown in E and F, respectively. Notably, no signiﬁcant immunoreactivity with
anti-Zeb1 antibody was observed in non-cancerous epithelium of gallbladder
bladder (G). Original magniﬁcations, 100 (E, F, and G), 200 (A and B), and 400
(C and D).
Y. Adachi et al. / FEBS Letters 583 (2009) 430–436 435ing to the sequence 50-CACCT-30 [26,40–43]. Sekido et al. exten-
sively examined the Zeb1 (delta-EF1)-binding sequence and found
that Zeb1 binds strongly to 50-CACCTG-30 and 50-CACCTT-30, mod-
erately to 50-CACCTA-30, but weakly or not at all to 50-CACCTC-30
[43].
The promoter segment has a canonical Zeb1 binding sequence,
50-CACCTG-30, but neither 50-CACCT-30 nor 50-CACCTA-30 sequence.
The ﬁndings of EMSA in the present study showed that replace-
ment of the 50-CACCTG-30 sequence with the 50-AAATTT-30 se-
quence markedly inhibited Zeb1 binding to the T-cadherin
promoter region. These data indicates that the 50-CACCTG-30 se-
quence of the T-cadherin promoter is essential for Zeb1 regulation.
Exogenous Zeb1 expression decreased T-cadherin expression in
OCUG-1 gallbladder cancer cells. By contrast, siRNA silencing of
Zeb1 increased T-cadherin expression in NOZ cells. Moreover,
while expression of Zeb1 was found at sites of cancer invasion, that
of T-cadherin was found at non-invasive foci also suggesting that
over-expression of Zeb1 might repress T-cadherin expression in
gallbladder cancer.
Over-expression of Zeb1 is also found in colorectal [44] and
lung cancer [45], in which expression of T-cadherin is suppressed
[23,24,36]. These ﬁndings suggest that Zeb1 may repress T-cad-
herin expression in various cancers, as demonstrated in gallbladder
cancer.Recent studies have highlighted Zeb1 as one of the key mole-
cules responsible for EMT [12] and the invasive activity of cancer
cells [46]. Cadherin switching followed by activation of cancer
invasion is often found in EMT [47]. It is known that E-cadherin
is down-regulated while expression of N-cadherin is increased
during cancer progression [47]. T-cadherin is also down-regulated
during the progression of various types of cancer.
OCUG-1 cells expressed E-cadherin but not N-cadherin, while
NOZ cells expressed N-cadherin but not E-cadherin. OCUG-1 cells
proliferated in monolayer sheets with epithelial cell phenotype,
whereas NOZ cells were spindle-shaped, a feature of mesenchymal
cells. In the present study, silencing of T-cadherin resulted in mor-
phological change from epithelial to mesenchymal-like cells and
decreased collagen-gel invasive activity in OCUG-1 cells. By con-
trast, exogenous T-cadherin expression reduced the collagen-gel
invasion activity of NOZ cells. Lee et al also reported that restora-
tion of T-cadherin markedly inhibits breast cancer cell invasion
[48]. These ﬁndings together suggest that Zeb1-mediated T-cad-
herin suppression may play a role in EMT and could increase can-
cer cell invasion.
T-cadherin is a glycosyl phosphatidyl inositol (GPI)-linked sur-
face membrane protein [13], and lacks the cytoplasmic domain re-
quired for the homophilic binding activity of classical cadherins
[16]. It has been thought that T-cadherin does not mediate cell-cell
adhesion, as found for E-cadherin in physiological conditions. Con-
sistent with this, a recent study based on NMR structural examina-
tion clearly demonstrated that T-cadherin is monomeric in both
the presence and absence of calcium [21], and may thus lack hom-
ophilic cell-cell adhesive activity. These studies suggest that a no-
vel molecular mechanism not involving intracellular adhesion may
be responsible for cancer invasion followed by loss of T-cadherin.
We are now examining the molecular proﬁle of gallbladder cancer
cells with or without induction of T-cadherin using a tetracycline-
induced T-cadherin expression system.
In summary, the present study yielded three ﬁndings. First,
Zeb1 was overexpressed in many gallbladder cancers, especially
at sites of cancer invasion. Second, Zeb1 participated in the silenc-
ing of T-cadherin through E2-box elements of the T-cadherin pro-
moter. Third, T-cadherin may be involved in EMT and a negative
regulator of gallbladder cancer cells.
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